Tolerance and rebound insomnia with rapidly eliminated hypnotics: a meta-analysis of sleep laboratory studies
The DOI matches its Crossref record.
Abstract
Differences in development of tolerance and occurrence of rebound insomnia have been well established between rapidly and slowly eliminated benzodiazepine hypnotics. Based on meta-analytic methodology, this study assesses whether there are such differences among the rapidly eliminated benzodiazepine and benzodiazepine-like hypnotics (brotizolam, midazolam, triazolam, zolpidem and zopiclone). All sleep laboratory studies of these drugs (n= 137) published from 1966 to 1997 were obtained, mainly through a MEDLINE search. Rigorous selection criteria resulted in the inclusion of 75 studies employing 1276 individuals (804 insomniacs and 472 healthy volunteers). Using a mixed effects regression model, reliable estimation of the effects on insomniacs of the recommended dose of each drug could be obtained. All five rapidly eliminated hypnotics showed statistically significant initial efficacy. Tolerance with intermediate and long-term use was clearly developed with triazolam and was only marginal with midazolam and zolpidem; it could not be estimated for brotizolam or zopiclone because of insufficient data. Rebound insomnia on the first withdrawal night was intense with triazolam and mild with zolpidem; data were unavailable for brotizolam and inadequate for midazolam and zopiclone. In conclusion, there are differences among the rapidly eliminated hypnotics with respect to tolerance and rebound insomnia suggesting that, in addition to short elimination half-life, other pharmacological properties are implicated in the mechanisms underlying these side-effects. Int Clin Psychopharmacol 14:287-303 © 1999 Lippincott Williams & Wilkins
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These symptoms are more severe following withdrawal from short rather than long half-life BZDs [39,40,41,42,43].”
From Cognitive behavioral therapy and acceptance and commitment therapy for the discontinuation of long-term benzodiazepine use in insomnia and anxiety disorders (2021) · cites this paper as [41]
In the citing paper
“However, 75% of patients who withdrawn after long-term use of benzodiazepines developed new withdrawal symptoms regardless of rapidly eliminated or slowly eliminated compounds [51].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [51]
In the citing paper
“However, this may be an overgeneralization, as a review showed that tolerance in human subjects only marginally emerged after chronic treatment with the short-acting drugs midazolam and zolpidem, even though the short-acting drug triazolam was associated with tolerance [48].”
From Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective Receptor Modulators? (2012) · cites this paper as [48]
Citations
Cites
Still being checked.
Cited by
Comparative Meta-Analysis of Pharmacotherapy and Behavior Therapy for Persistent Insomnia
Smith, M. T., Perlis, M. L., Park, A., Smith, M. S., Pennington, J., Giles, D. E., & Buysse, D. J. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.1.5 · Cited by 863
The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023
Riemann, D., Espie, C. A., Altena, E., Arnardottir, E. S., Baglioni, C., Bassetti, C. L. A., Bastien, C., Berzina, N., Bjorvatn, B., Dikeos, D., et al. (2023) · Journal of Sleep Research · doi:10.1111/jsr.14035 · Cited by 834
Self-citationWilson, S., Nutt, D., Alford, C., Argyropoulos, S., Baldwin, D., Bateson, A., Britton, T., Crowe, C., Dijk, D.-J., Espie, C., et al. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110379307 · Cited by 634
Irwin, M. R., Cole, J. C., & Nicassio, P. M. (2006) · Health Psychology · doi:10.1037/0278-6133.25.1.3 · Cited by 537
The Efficacy and Safety of Drug Treatments for Chronic Insomnia in Adults: A Meta-Analysis of RCTs
Buscemi, N., Vandermeer, B., Friesen, C., Bialy, L., Tubman, M., Ospina, M., Klassen, T. P., & Witmans, M. (2007) · Journal of General Internal Medicine · doi:10.1007/s11606-007-0251-z · Cited by 448
“among studies, ( 4 ) the long-term efficacy and safety of drug treatments for the management of chronic insomnia, and (5) the development of a threshold for a clinically significant treatment effect in the management of chronic insomnia, such that statistically significant findings can be put into clinical context.”
Background
Metadata
- Authors
- Soldatos, C. R., Dikeos, D. G., & Whitehead, A.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- University of Reading (GB)
- Corresponding author
- Soldatos, Constantin R.
- Venue
- International Clinical Psychopharmacology
- Published
- 1999-09
- Volume
- 14
- Issue
- 5
- Pages
- 287-304
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2040290595
- Cited by
- 154
- References
- 0
- Citations by year
- 2026: 7 · 2025: 1 · 2024: 3 · 2023: 6 · 2022: 4 · 2021: 5 · 2020: 4 · 2019: 6 · 2018: 7 · 2017: 5 · 2016: 2 · 2015: 3 · 2014: 4 · 2013: 7 · 2012: 5
- FWCI
- 8.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- rebound insomnia, drug tolerance, benzodiazepine hypnotics, triazolam, zolpidem, midazolam, brotizolam, zopiclone, elimination half-life, hypnotic withdrawal, insomnia treatment
- MeSH terms
- Benzodiazepines, Half-Life, Humans, Hypnotics and Sedatives, Sleep Initiation and Maintenance Disorders, Recurrence, Substance Withdrawal Syndrome, Anti-Anxiety Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tolerance and rebound insomnia with rapidly eliminated hypnotics: a meta-analysis of sleep laboratory studies. https://app.cochat.ai/papers/10.1097/00004850-199909000-00004
- The paper
- Soldatos, C. R., Dikeos, D. G., & Whitehead, A. (1999). Tolerance and rebound insomnia with rapidly eliminated hypnotics: a meta-analysis of sleep laboratory studies. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-199909000-00004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.